This topical IVIG treatment reduced infection in 12 days at a rate of greater than 95 and 70%, respectively; the patient with the STAT1 mutation had had chronic mucocutaneous candidiasis since she was 8 months old and severe oral candidiasis resistant to voriconazole. Here, STAT1 is linked to oral candidiasis.